Best Diffuse Large B Cell Lymphoma Podcasts (2025)

1
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19 ... 20:57

5d ago20:57

20:57

In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acut…

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

12d ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 18:31

3d ago18:31

18:31

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School i…

1
How I Treat Transfusion Medicine (part 2) 33:57

3h ago33:57

33:57

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George. Find the full published review series in Volume 145 Issue 20 of Blood Journal.By American Society of Hematology

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

11d ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
When to STOP Treatment for Immune Thrombocytopenia in Patients Experiencing a Complete Response on Thrombopoietin Receptor Agonists 10:34

11d ago10:34

10:34

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-t…

1
How I Treat Transfusion Medicine (part 1) 32:12

4d ago32:12

32:12

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RB…

1
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT 18:15

12d ago18:15

18:15

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differe…

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

12d ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

12d ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease 19:58

19d ago19:58

19:58

In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickl…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

22d ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Metastatic Breast Cancer: Treatment Updates 1:05:14

14d ago1:05:14

1:05:14

- Overview of Metastatic Breast Cancer- Current Standard of Care- New Treatment Approaches- Updates on Clinical Trials- How Clinical Research Increases Your Treatment Options- Biomarkers, Diagnostic Testing & Technologies: Why They Are Important in Informing Treatment Decisions for Metastatic Breast Cancer- Preventing & Managing Treatment Side Effe…

1
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature 18:12

26d ago18:12

18:12

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffu…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

19d ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

19d ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

19d ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
Understanding HER2 Low Breast Cancer 55:26

25d ago55:26

55:26

- Overview of HER2 Low Breast Cancer- What is the HER2 Status of My Cancer? What does this Mean?- Diagnostic Testing: What is an Immunohistochemistry (IHC) Test or Fluorescence In Situ Hybridization (FISH) Test- The Role of the Pathologist- The Role of the Genetic Counselor- Standard Treatment Options, Including Targeted Therapy- How Biomarker Test…

1
No Scientific Link Found Between Sickle Cell Trait and Sudden Death 21:07

23d ago21:07

21:07

In this episode, Contributing Editor Samuel Wilson, MD, MSCR, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Exc…

1
Diverse Populations Living with Multiple Myeloma 57:20

26d ago57:20

57:20

- Overview of Diverse Populations Living with Multiple Myeloma- How Race May Impact Your Access to the Treatment of Multiple Myeloma- Social Determinants of Health, Including Languages Spoken & Health Literacy- Current Standard of Care- New & Emerging Treatments- The Role of Transplantation- Preventing & Managing Treatment Side Effects, Symptoms, D…

1
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell ... 19:06

1M ago19:06

19:06

In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients wit…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

1M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

1M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

1M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

1M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

1M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

1M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

1M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

1M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
How I Treat Myeloproliferative Neoplasms 38:36

1M ago38:36

38:36

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat se…

1
The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL 18:49

1M ago18:49

18:49

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options…

1
Trends in Oncology & Treatment Planning: A Guide to Getting the Best Care 56:59

1M ago56:59

56:59

- Understanding Your Cancer Diagnosis & Treatment Options- Clinical Trial Opportunities: How Research Increases Treatment Options- Factors That May Affect Treatment Planning- How Your Health Care Team May Help You Address Your Care- Participating in Decisions about Your Treatment Plans, Side Effect Prevention & Management- Understanding the Role of…

1
Trends in Oncology & Treatment Planning: A Guide to Getting the Best Care 56:59

1M ago56:59

56:59

- Understanding Your Cancer Diagnosis & Treatment Options- Clinical Trial Opportunities: How Research Increases Treatment Options- Factors That May Affect Treatment Planning- How Your Health Care Team May Help You Address Your Care- Participating in Decisions about Your Treatment Plans, Side Effect Prevention & Management- Understanding the Role of…

1
Trends in Oncology & Treatment Planning: A Guide to Getting the Best Care 56:59

1M ago56:59

56:59

- Understanding Your Cancer Diagnosis & Treatment Options- Clinical Trial Opportunities: How Research Increases Treatment Options- Factors That May Affect Treatment Planning- How Your Health Care Team May Help You Address Your Care- Participating in Decisions about Your Treatment Plans, Side Effect Prevention & Management- Understanding the Role of…

1
Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed ... 20:59

2M ago20:59

20:59

In this week's episode we’ll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refract…

1
Advances in the Treatment of Colorectal Cancer 1:00:34

2M ago1:00:34

1:00:34

- Overview of Colorectal Cancer- Current Standard of Care- The Increasing Number of Younger People Being Diagnosed with Colorectal Cancer- New Treatment Approaches- Predicting Response to Treatment- Staging & Biomarker Testing- The Role of Targeted Cancer Therapies- Clinical Trial Updates: How Research Contributes to Treatment Options- Preventing &…

1
Coping with the Stresses of Caregiving When Your Loved One Has Multiple Myeloma 57:37

2M ago57:37

57:37

- Overview of the Treatment of Multiple Myeloma- Deciding to Become a Caregiver- Your Important Role in Decision Making- Challenges in Communicating with the Health Care Team- Your Role in Adherence: Weekends, Holidays & Vacations- Coping with Each Day, on Special Occasions, Anniversaries & Birthdays- Managing Family, Friends, & Traditions- Long-Di…

1
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL 15:26

2M ago15:26

15:26

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, …

1
Blood Bonus Episode: What is a Blood group? 14:59

2M ago14:59

14:59

In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype”, speaks with Blood Associate Editor Dr. Erica Wood about the discovery of the genetic basis for the inherited AnWj-ne…

1
Does This Star ‘GLO’? Taking Aim at Second-Line Diffuse Large B-Cell Lymphoma With Glofitamab Plus Gemcitabine and Oxaliplatin 20:16

2M ago20:16

20:16

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and an associate professor of medicine at Harvard …

1
Current Perspectives on the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) 57:04

2M ago57:04

57:04

- Review of Chronic Lymphocytic Leukemia- Significant Role of Testing in Informing Your Treatment Choices- First-Line Treatment Options- Treatment of Relapsed & Refractory CLL- Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments- Current Perspectives on New & Emerging Treatments of CLL- Updates on Clinical Trials & Their Si…

1
Progress in the Treatment of Multiple Myeloma 54:00

2M ago54:00

54:00

- Discussion of the Progress in the Treatment of Multiple Myeloma- Current Standard of Care, Including Clinical Trial Updates- New & Emerging Treatments- The Role of Transplantation- Preventing & Managing Treatment Side Effects, Symptoms, Discomfort & Pain- Reducing Complications of Bone Disease- Talking with Your Treatment Team About Quality-of-Li…

1
Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle ... 19:16

2M ago19:16

19:16

In this week's episode, we’ll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles: Itacitinib…

1
Breast Cancer in Younger Women: New Treatment Options 59:56

2M ago59:56

59:56

- Overview of Breast Cancer in Younger Women, Including Diagnosing, Staging & ER, PR, HER2 Status- Unique Issues for Younger Women Living with Breast Cancer- Precision Medicine & Sequencing of Treatment - Genetic Testing, Including BRCA Testing- What Informs Treatment Decisions & Options- Understanding Your Pathology Report- Updates on Clinical Tri…

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

2M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
Updates on CAR T-cell Therapies 53:09

2M ago53:09

53:09

- Overview of CAR T-Cell Therapies- Understanding CARs – Chimeric Antigen Receptors- When to Consider CAR T-Cell Therapies as a Treatment Choice- Clinical Trials for CAR T-Cell Therapies- Discussion of CAR T-Cell Therapies- Managing Potential Treatment Side Effects- Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care- Key Ques…

1
Updates on CAR T-cell Therapies 53:09

2M ago53:09

53:09

- Overview of CAR T-Cell Therapies- Understanding CARs – Chimeric Antigen Receptors- When to Consider CAR T-Cell Therapies as a Treatment Choice- Clinical Trials for CAR T-Cell Therapies- Discussion of CAR T-Cell Therapies- Managing Potential Treatment Side Effects- Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care- Key Ques…

1
Updates on CAR T-cell Therapies 53:09

2M ago53:09

53:09

- Overview of CAR T-Cell Therapies- Understanding CARs – Chimeric Antigen Receptors- When to Consider CAR T-Cell Therapies as a Treatment Choice- Clinical Trials for CAR T-Cell Therapies- Discussion of CAR T-Cell Therapies- Managing Potential Treatment Side Effects- Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care- Key Ques…

1
Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis 19:07

2M ago19:07

19:07

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome…

1
Breast Cancer in Men: Diagnosis, Treatment and Survivorship 50:53

2M ago50:53

50:53

- Overview of the Diagnosis & Treatment of Breast Cancer in Men- Detection of Breast Cancer in Men – Mammogram, Ultrasound, Biopsy- Grading & Staging of Breast Cancer- Understanding the Treatment of Breast Cancer in Men – Surgery, Radiation, Immunotherapy, Targeted Treatments- Definition of Genetics & Genomics of Breast Cancer in Men- Tools that He…

Podcasts Worth a Listen

Diffuse Large B Cell Lymphoma Podcasts

Podcasts Worth a Listen